Piramal Pharma Ltd

A sharp decline of 3.8% on 23 Mar 2026 dragged Piramal Pharma Ltd to a fresh 52-week low of Rs 133, extending a painful downtrend that has seen the stock lose over 41% in the past year, far outpacing the broader market's modest 5.5% decline.

Piramal Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from fair to attractive territory despite ongoing challenges in its financial performance and stock returns. With a current price of ₹138.55, close to its 52-week low of ₹134.70, the pharmaceutical small-cap’s price-to-earnings (P/E) ratio has plunged to a striking -128.57, signalling significant earnings pressure. This article analyses the evolving valuation landscape of Piramal Pharma in comparison to its sector peers and historical benchmarks, providing a comprehensive view for investors navigating the Pharmaceuticals & Biotechnology space.

Piramal Pharma Ltd’s shares declined to a fresh 52-week low of Rs.134.8 today, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.

Piramal Pharma Ltd’s shares declined to a fresh 52-week low of Rs.141.4 on 13 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.

Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Feb 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the company’s current position as of 13 March 2026, providing investors with the latest comprehensive analysis.

Piramal Pharma Ltd (PPLPHARMA) has witnessed a significant 13.7% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a fresh 52-week low in the stock price, reflecting growing bearish sentiment amid sustained selling pressure and underperformance relative to its sector and benchmark indices.

Piramal Pharma Ltd’s shares have declined to a fresh 52-week low, closing near Rs 144.85 on 12 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low price reflects a 1.62% proximity to the absolute 52-week low of Rs 142.95, underscoring persistent pressures on the company’s valuation within the Pharmaceuticals & Biotechnology sector.

Piramal Pharma Ltd (PPLPHARMA) witnessed a notable 11.9% increase in open interest in its derivatives segment on 12 Mar 2026, signalling heightened market activity and shifting investor positioning. This surge accompanies a sharp 6.05% decline in the stock price, which hit a fresh 52-week low of Rs 144.96, underperforming its sector and broader indices. The data suggests a growing bearish sentiment among traders, with implications for near-term directional bets and risk management strategies.

Piramal Pharma Ltd commenced trading today with a pronounced gap down, opening at a price 8.45% lower than its previous close, reflecting heightened market apprehension following recent developments. The stock hit a new 52-week low of Rs.142.95, underperforming its sector and continuing a short-term downward trend.

Piramal Pharma Ltd’s shares declined sharply to a fresh 52-week low of Rs.142.95 on 2 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a series of financial setbacks and valuation concerns.

Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Piramal Pharma Ltd has been downgraded from a Sell to a Strong Sell rating as of 18 Feb 2026, reflecting deteriorating fundamentals and a bearish technical outlook. The company’s financial performance has weakened significantly, with negative quarterly results and poor debt servicing ability, while technical indicators have shifted to a more pessimistic stance. This comprehensive analysis explores the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that triggered this rating change.

Piramal Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest intraday decline, the stock’s technical profile reveals growing downside pressure, underscored by deteriorating moving averages and bearish MACD readings, raising concerns for investors amid a challenging pharmaceutical sector backdrop.

Piramal Pharma Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite ongoing financial challenges. The revision is driven primarily by a change in technical indicators, while fundamental concerns around profitability and debt servicing persist. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced the rating adjustment.

Piramal Pharma Ltd has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook, reflecting nuanced changes in key indicators such as MACD, RSI, and moving averages. Despite a modest day gain of 1.56%, the stock’s broader trend remains cautious amid mixed signals from weekly and monthly charts.